Zenotech Laboratories Ltd
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]
- Market Cap ₹ 427 Cr.
- Current Price ₹ 70.0
- High / Low ₹ 81.0 / 49.6
- Stock P/E 37.8
- Book Value ₹ 14.2
- Dividend Yield 0.00 %
- ROCE 18.4 %
- ROE 15.1 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 24.4% CAGR over last 5 years
- Debtor days have improved from 43.2 to 28.6 days.
Cons
- Stock is trading at 4.94 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 3 | 3 | 4 | 2 | 2 | 11 | 13 | 26 | 22 | 37 | 42 | 43 | |
7 | 24 | 20 | 24 | 10 | 13 | 19 | 17 | 17 | 16 | 19 | 22 | 23 | |
Operating Profit | -5 | -20 | -17 | -20 | -8 | -10 | -8 | -4 | 9 | 6 | 17 | 21 | 19 |
OPM % | -221% | -673% | -618% | -492% | -372% | -462% | -71% | -27% | 35% | 28% | 48% | 49% | 46% |
-1 | -0 | 2 | 0 | 0 | 2 | 2 | 5 | 8 | 0 | 1 | 1 | 1 | |
Interest | 1 | 1 | 5 | 7 | 8 | 8 | 2 | 0 | 1 | 2 | 1 | 0 | 0 |
Depreciation | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 7 | 7 | 7 |
Profit before tax | -10 | -26 | -23 | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 10 | 15 | 13 |
Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -124% | 20% | |
-10 | -26 | -23 | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 22 | 12 | 11 | |
EPS in Rs | -1.68 | -4.18 | -3.75 | -4.99 | -3.14 | -3.26 | -1.94 | -0.51 | 1.77 | -0.20 | 3.63 | 1.90 | 1.85 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 30% |
5 Years: | 31% |
3 Years: | 18% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 24% |
3 Years: | 38% |
TTM: | -49% |
Stock Price CAGR | |
---|---|
10 Years: | 8% |
5 Years: | 26% |
3 Years: | 15% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 18% |
Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 34 | 34 | 34 | 34 | 34 | 34 | 61 | 61 | 61 | 61 | 61 | 61 | 61 |
Reserves | 17 | -8 | -31 | -62 | -80 | -100 | -19 | -22 | -11 | -13 | 10 | 21 | 26 |
5 | 16 | 47 | 54 | 54 | 54 | 0 | 20 | 21 | 21 | 6 | 0 | 0 | |
12 | 25 | 20 | 37 | 45 | 62 | 40 | 25 | 15 | 17 | 17 | 19 | 17 | |
Total Liabilities | 68 | 67 | 70 | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 94 | 101 | 104 |
62 | 59 | 56 | 52 | 48 | 47 | 44 | 43 | 49 | 74 | 71 | 65 | 68 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 17 | 29 | 2 | 0 | 5 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
6 | 8 | 14 | 12 | 5 | 4 | 35 | 25 | 8 | 9 | 23 | 31 | 35 | |
Total Assets | 68 | 67 | 70 | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 94 | 101 | 104 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-2 | -10 | -24 | -8 | -5 | 2 | -16 | -14 | 11 | 6 | 18 | 21 | |
-0 | -0 | -0 | 0 | 6 | -1 | -3 | -16 | -21 | -5 | -2 | -6 | |
2 | 10 | 30 | 7 | -1 | -1 | 47 | 15 | -3 | 0 | -16 | -6 | |
Net Cash Flow | 0 | -0 | 5 | -1 | -0 | 0 | 28 | -15 | -12 | 1 | -0 | 9 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 12 | 8 | 12 | 36 | 62 | 0 | 0 | 66 | 26 | 62 | 39 | 29 |
Inventory Days | 82 | 375 | 562 | 233 | 305 | 202 | 374 | 294 | ||||
Days Payable | 650 | 732 | 488 | 222 | 816 | 1,128 | 2,468 | 2,089 | ||||
Cash Conversion Cycle | -556 | -348 | 86 | 46 | -449 | -926 | -2,094 | -1,728 | 26 | 62 | 39 | 29 |
Working Capital Days | -2,280 | -2,916 | -2,417 | -3,295 | -8,062 | -10,395 | -1,219 | -537 | -171 | -164 | -106 | -99 |
ROCE % | -13% | -48% | -39% | -62% | -66% | -62% | -6% | 8% | 0% | 15% | 18% |
Documents
Announcements
- Board Meeting Intimation for Consideration And Approval Of Audited Standalone Financial Results Of The Company For The Fourth Quarter And Financial Year Ended March 31, 2024 1d
- Compliance Certificate Under Regulation 40(9) & (10) Of The SEBI (LODR) Regulations, 2015 2d
- Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended March 31, 2024 6 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Submission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2024
- Shareholder Meeting / Postal Ballot-Outcome of AGM 6 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products